Clinical trial NCT04495127: Selumetinib Paediatric NF1 Japan Study
Official title: A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Japanese Paediatric Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable and Symptomatic Plexiform Neurofibromas (PN)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Neurofibromatosis Type 1
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2020-07-31
Enrollment: 12
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase I open label study designed to evaluate the safety, tolerability, PK and efficacy of selumetinib in Japanese paediatric patients with neurofibromatosis type 1 and inoperable and symptomatic plexiform neurofibroma.


Eligibility criteria: Key Inclusion Criteria:

* Three years of age or older, and less than or equal to 18 years of age at the time of obtaining informed consent. BSA greater than or equal to 0.55 m2, and able to swallow the whole study drug (capsules) without entire contents unpacked from the capsules.
* NF1 and inoperable and symptomatic PN who have PN-related morbidities (symptom and/or complications), as judged by the investigator.
* Inoperable PN is defined as PN that cannot be surgically completely removed without risk for substantial morbidity due to encasement of, or close proximity to, vital structures, invasiveness, or high vascularity of the PN.
* A PN is defined as a neurofibroma that has grown along the length of a nerve and may involve multiple fascicles and branches. A spinal PN involves two or more levels with connection between the levels or extending laterally along the nerve.
* In addition to PN, subjects must have at least 1 other diagnostic criterion for NF1 as follows:

  1. Six or more café-au-lait macules \>5 mm in greatest diameter in pre-pubertal individuals and \>15 mm in greatest diameter in post-pubertal individuals.
  2. Freckling in the axillary or inguinal regions.
  3. Optic glioma.
  4. Two or more Lisch nodules (iris hamartomas).
  5. A distinctive osseous lesion such as sphenoid dysplasia or tibial pseudarthrosis.
  6. A first-degree relative with NF1.
* At least one measurable typical or nodular PN in principle, defined as a lesion of at least 3 cm measured in one dimension.
* Adequate organ/haematological function

Key Exclusion Criteria:

* Evidence of malignant peripheral nerve sheath tumour.
* Prior malignancy (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, low grade optic pathway gliomas associated with NF1 which does not require systemic treatment or other cancer from which the subject had been disease free for ≥2 years or which would not have limited survival to \<2 years) or other cancer requiring treatment with chemotherapy or radiation therapy.
* Clinically significant cardiovascular disease
* Known history of human immunodeficiency virus, serologic status reflecting active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, or any uncontrolled active systemic infection
* Subjects with clinically significant ophthalmological findings/conditions
* Inability to undergo MRI and/or contraindication for MRI (i.e. prosthesis or orthopaedic or dental braces that would interfere with volumetric analysis of target PN on MRI).
* Have refractory nausea and vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease), or significant bowel resection that would adversely affect the absorption/bioavailability of the orally administered study medication.
* Receiving supplementation with vitamin E greater than 100% of the daily recommended dose.
* Receiving herbal supplements or medications known to be strong inhibitors or inducers of the cytochrome P450 (CYP) 3A4 enzymes unless such products can be safely discontinued at least 14 days before the first dose of study medication.

Primary outcomes:
measure: Safety and tolerability in terms of adverse events
timeFrame: From obtaining the first informed consent until 30 days after the last dose (Selumetinib). Expected duration is approximately 2 years.
Secondary outcomes:
measure: Maximum plasma concentration (Cmax)
timeFrame: From obtaining the first informed consent until 30 days after the last dose (Selumetinib). Expected duration is approximately two years.
measure: Area under the plasma concentration-time curve (AUC)
timeFrame: From obtaining the first informed consent until 30 days after the last dose (Selumetinib). Expected duration is approximately two years.
measure: Overall response rate
timeFrame: Assessed at every 4 cycles until drug permanently discontinued. Expected duration is approximately 2 years. Each cycle is 28 days.
measure: Duration of response
timeFrame: Assessed at every 4 cycles until drug permanently discontinued. Expected duration is approximately 2 years. Each cycle is 28 days.
measure: Clinical Global Impression of Change (CGIC)
timeFrame: Assessed at every 2 cycles for the first year and every 4 cycles until drug permanently discontinued. Expected duration is approximately 2 years. Each cycle is 28 days.
measure: Total scale score of Paediatric Quality of Life Inventory (PedsQL; self- and parent-reported)
timeFrame: Assessed at every 4 cycles until drug permanently discontinued. Expected duration is approximately 2 years. Each cycle is 28 days.
Other outcomes:
Locations:
city: Minato-ku
country: Japan
facility: Research Site
city: Nagoya-shi
country: Japan
facility: Research Site
city: Setagaya-ku
country: Japan
facility: Research Site
Study officials:
References: